New immune aging drug brings Longevity and C19 hope

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Phase 2-ready drug can treat and reverse immune aging, BioAge claims.

BioAge Labs‘ in-licensed clinical-stage therapy has potential for treating immune aging in older patients hospitalised with COVID-19, tackling both morbidity and mortality, the biotech company claims.

Longevity.Technology: Back in May we covered BioAge Labs’ exclusive worldwide licence agreement with Taisho Pharmaceutical to develop and commercialise Taisho’s clinical-stage HIF-PH inhibitor to target multiple diseases of aging.

Not resting on their laurels at all, the company is responding to the global pandemic with a drug that has the potential to treat immune aging in older patients hospitalised with COVID-19. But the research has wider ramifications, as one of the key effects of aging is the dysregulation of the immune system caused by immunosenescence and inflammaging; being able to correct that dysregulation would significantly benefit both healthspan and lifespan.

BioAge’s compound, BGE-175, is an orally-administered inhibitor of the prostaglandin D2 DP1 signalling pathway associated with increased risk of mortality, and susceptibility to infections. The company recently generated preclinical data showing significant immune-modulating and anti-viral activity of BGE-175 which resulted in 100% survival in a preclinical model of the SARS 1 virus.

 


 

BioAge Labs revealed that in addition to fully-protecting infected mice from death and improving morbidity, treated mice showed a 10-fold decrease in virus in their lungs.

 


 

In a statement, BioAge Labs revealed that in addition to fully-protecting infected mice from death and improving morbidity, treated mice showed a 10-fold decrease in virus in their lungs. BGE-175 has demonstrated clinical activity and safety in a large number of subjects across multiple clinical trials for another indication.

“Aging is the largest risk factor for COVID-19 morbidity and mortality,” said Kristen Fortney, PhD, BioAge’s CEO. “BGE-175 has the potential to restore the function of several key immune mechanisms that become dysregulated with aging, and that are critical to mount an effective response to major immune challenges such as COVID-19, SARS, and pandemic influenza. We plan to advance BGE-175 into a Phase 2 clinical trial in COVID-19 patients to evaluate whether its unique mechanism can improve patient outcomes by directly targeting immune aging.”

 


 

“… the potential to address other diseases driven by immune aging … a growing pipeline of promising therapeutics that BioAge will bring forward to treat diseases of aging.”

 


 

Dr Fortney added: “Our AI-driven analysis of our proprietary human aging data maps out how the immune system is dysregulated during aging. Beyond COVID-19, BGE-175 has the potential to address other diseases driven by immune aging. BGE-175 is the second in a growing pipeline of promising therapeutics that BioAge will bring forward to treat diseases of aging.”

The pathways impacted by BGE-175 are linked to lifespan and healthspan in BioAge’s proprietary human aging data. The prostaglandin pathway, as well as several key components of the immune response to viral challenge, are significantly associated with Longevity and multiple functional measures. Inhibition of PGD2 DP1 receptor signaling impacts multiple immune mechanisms, and BioAge’s preclinical studies demonstrate that BGE-175 inhibits neutrophil migration and that DP1 inhibition boosts dendritic cell function, both of which counteract known aspects of immune aging, and are also therapeutically promising for COVID-19 and other respiratory infections.

We’ll be speaking to Dr Fortney next month to find out about the next steps for BGE-175 and what else is in the BioAge pipeline.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Printers that can now print DNA

DNA Script obtains CE Mark for SYNTAX DNA printing platform. DNA Script, a leader in Enzymatic DNA Synthesis (EDS), announced the CE marking of its SYNTAX System, the...

A brain fitbit that can spot Alzheimer’s with up to 94% accuracy

Altoida raising new financing for augmented reality cognitive assessment platform that dramatically improves early detection of Alzheimer’s and other neurodegenerative diseases. Earlier this year, AR-powered...

Insilico starts human trial with AI-discovered drug

First human dosed with AI-discovered novel molecule based on an AI-discovered novel target. Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery company, has announced that the...

    Subscribe to our newsletter